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Abstract
Background: The burden of cancer metastases within an individual is commonly used to clinically
characterize a tumor's biological behavior. Assessments like these implicitly assume that spurious
effects can be discounted. Here the influence of chance on the burden of metastasis is studied to
determine whether or not this assumption is valid.
Methods: Monte Carlo simulations were performed to estimate tumor burdens sustained by
individuals with cancer, based upon empirically derived and validated models for the number and
size distributions of metastases. Factors related to the intrinsic metastatic potential of tumors and
their host microenvironments were kept constant, to more clearly demonstrate the contribution
from chance.
Results: Under otherwise identical conditions, both the simulated numbers and the sizes of
metastases were highly variable. Comparable individuals could sustain anywhere from no
metastases to scores of metastases, and the sizes of the metastases ranged from microscopic to
macroscopic. Despite the marked variability in the number and sizes of the metastases, their
respective growth times were rather more narrowly distributed. In such situations multiple occult
metastases could develop into fully overt lesions within a comparatively short time period.
Conclusion: Chance can have a major effect on the burden of metastases. Random variability can
be so great as to make individual assessments of tumor biology unreliable, yet constrained enough
to lead to the apparently simultaneous appearance of multiple overt metastases.
Background
The burden of metastatic disease can be an important
determinant in cancer management [1]. With many of the
common epithelial cancers, successful resection of the pri-
mary tumor may be all that is required for cure, provided
that there are no metastases. If the numbers of metastases
are limited, it may be possible to resect them along with
the primary tumor for curative intent [2-4]. Moreover,
adjuvant therapy may cure individuals who might other-
wise succumb, provided that the metastatic burden is
small and their disease is responsive to therapy [5,6].
In those individuals who have had their metastatic disease
resected, the number of metastases removed tends to have
an adverse correlation with survival [3,7-10]. In addition,
the total volume of resected metastases may provide an
even stronger prognostic indicator [11]. Clinicians have
often considered the number of metastases sustained by
an individual to be a biological measure of intrinsic tumor
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behavior [12-16]. In keeping with this view, both clini-
cians [17] and experimentalists [18-22] have come to
equate the metastatic potential of tumors with the num-
bers of organ metastases.
There is, however, a critical distinction between human
clinical observations and animal experiments: Animal
experiments can be repeated under more or less uniform
conditions; human observations are usually isolated and
more heterogeneous. Even so, controlled animal experi-
ments tend to exhibit considerable heterogeneity in the
numbers of hematogenous metastases [18,21,23]. In
some cases the observed experimental heterogeneity can
be attributable to pre-existent variant cells within tumor
cell populations [18,24], but even within groups of syn-
geneic animals treated with the same tumor cells, the
numbers of resultant metastases can be quite variable
[25,26]. The metastatic heterogeneity, evident with these
animal studies, is also evident with human studies [27].
This pattern can be attributed to physiologic heterogenei-
ties in regional organ blood flow and, combined with
counting (Poisson) statistics, the two processes can be
used to explain the disparities in the numbers of haema-
togenous metastases evident to individuals under other-
wise similar conditions [28,29].
Human autopsy studies have also revealed that the sizes
of metastases within individuals can be quite variable
[17,30]. In individuals with multiple metastases the fre-
quency distribution for the sizes of their metastases
approximates a lognormal form, which presumably
relates to a normal distribution for the growth times of
metastases, provided that the growth of the secondary
deposits is approximately exponential. These normally
distributed growth times can, in turn, be explained by the
summation of the times required for the multiple sequen-
tial steps deemed necessary for tumor growth and metas-
tasis [31].
On this basis, both the number of metastases and the sizes
of metastases can manifest random influences, in addi-
tion to being affected by the tumor's metastatic potential
and the host microenvironment. Since both the numbers
of metastases and the total tumor burden have been rep-
resented as measures of tumor biology [11-16], it would
be important to determine whether or not these addi-
tional spurious influences might obscure the biological
assessments of malignant behavior.
The central point to be illustrated here is that biologically
similar tumors may give rise to highly variable numbers or
volumes of metastases. Because of this, the clinically
apparent metastatic burden may not provide a good
measure of the biological characteristics of a tumor. Ani-
mal experiments have shown that the metastatic burden
does indeed reflect the biological properties of a tumor,
but spurious influences are commonly evident within
such experiments [18,21,23]. For this reason animal
experiments must be repeated a number of times in order
to ascertain the biological properties and to account for
chance variations. Clinicians are not able to do this when
assessing the biological potential of an individual's can-
cer. Clinical decisions may be made on the basis of the
evident burden of disease, without knowledge as to the
degree that chance might have influenced the clinical
presentation. For this reason it would be important to
demonstrate the potential influence that chance might
have on the metastatic burden.
To this end models for the number distribution [29] and
size distribution [31] of hematogenous metastases will be
utilized here to simulate the metastatic burden within a
hypothetical series of identical cancer patients. Since it
was not possible to control all the biological and temporal
variables in actual human clinical series, simulation was
chosen as the most practical means to assess the heteroge-
neity in metastatic burden that could be attributable to
chance.
Methods
Monte Carlo simulations were performed for the numbers
of hematogenous metastases within individuals where the
intrinsic biological conditions of the tumor and the host
microenvironment were presumed to remain constant by
maintaining the same mean and variance for the number
of metastases in each simulation. Granted, this approach
represents a simplification of the influence of tumor
growth factors, and their receptors, the production of ang-
iogenic factors, the capacity for motility and invasion, or
the capacity for aggregation and deformability which all
may affect a tumor's intrinsic capacity to metastasise and
proliferate [32]. The interplay of pararcrine and endocrine
growth factors, neovascularization, platelet aggregation
and the action of immune cells and their products are
additional factors that contribute to the host microenvi-
ronment [32] were similarly treated. The precise way that
these factors might exert their influences goes beyond the
aim of this manuscript, and a phenomenological
approach was taken instead. To this end the Poisson neg-
ative binomial (PNB) distribution can accurately repre-
sent the variations in the numbers of hematogenous
metastases sustained by individuals under otherwise iden-
tical conditions [29], and it was thus used to represent the
frequency distribution for the numbers of metastases (see
the Additional file 1 for details regarding the PNB distri-
bution). In this model, variations in the numbers of
metastases can be attributed to both random chance and
to heterogeneity in regional organ blood flow [28,33].BMC Cancer 2005, 5:138 http://www.biomedcentral.com/1471-2407/5/138
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The simulation parameters were chosen to reflect a mean
number of about 8 metastases, and a variance of 57
metastases2. This was within the range of observation of
controlled metastasis experiments of the murine B16 F10
melanoma in lung [29], and well within the range of the
much more heterogeneous clinical data from humans
draw from lung and liver metastases secondary to sarco-
mas, lung carcinomas, and various gastrointestinal carci-
nomas [27]. This choice of parameters also afforded a
sizeable fraction of cases with no metastases and was
made with the view that the mean number of resultant
metastases was in itself not critical, since the aim of the
simulation was to illustrate the variability in the numbers
of metastases that might occur, under otherwise constant
intrinsic biological conditions.
Admittedly the choice of parameters here was arbitrary,
and designed to illustrate (not to prove) the potential var-
iability in the numbers of metastases. In simulations such
as these, the end results are predetermined by the choice
of models and parameters. However, in order to provide
realistic results, the models and parameters used were
chosen to emulate laboratory and clinicopathological
observation as closely as possible. Because the human
data reflected populational heterogeneity, with respect to
growth rates of primary tumors and their metastases and
the rates of metastatic dissemination, as well as differ-
ences in times of the onset of the primary tumor relative
to the assessment of the numbers of metastases of each
individual's disease, these human data could serve only as
an outside bounds for the potential ranges of these
parameters. Controlled experiments from the murine B16
F10 melanoma were extrapolated upon to provide some-
what closer bounds for the parameter choices.
A second set of Monte Carlo simulations was performed
to yield the size distribution of metastases expected within
individuals. Each metastasis was assumed to grow in
accordance with a stochastic pure birth process [34] (see
the Additional file 1). The growth times for the metastases
within any individual were further assumed to be nor-
mally distributed, in accordance with deductions from
previous human autopsy studies [31]. According to this
model, the size variations of the metastases could be
essentially attributed to random chance.
The growth times for the metastases, as defined from the
establishment of each nascent (and growing) metastasis
to the surgical removal of the primary tumor, was arbitrar-
ily assumed to have a mean and standard deviation (SD)
of 16 ± 1 volume doublings. After resection of the primary
tumor, the metastases were assumed to grow for an addi-
tional 12 doublings before they were counted and sized.
This sequence was chosen to emulate the clinical
sequence of resection of a primary tumor, performed in an
individual with no clinically detectable metastases, fol-
lowed by restaging after a set time interval. As well, and as
a first approximation, the growth rates of the metastases
were assumed to be the same as that of the primary tumor.
These two simulations were combined into a third simu-
lation, designed to provide the number and sizes of
metastases that could be anticipated within a group of
similar individuals. Fifty simulations were performed
where the biological properties intrinsic to the primary
tumor and the host microenvironment were assumed
constant.
A further calculation was performed, based upon the size
distribution of 4000 simulated metastases, in order to
determine the proportion of clinically detectable metas-
tases at various time intervals from the surgical resection
of the primary tumor. The growth parameters were the
same as in the previous calculations, and the clinical
detection threshold was arbitrarily set at 109 cells (~1
cm3).
Results
Figure 1 provides the results of the simulation for the
numbers of hematogenous metastases. About 14% of the
simulated cases sustained no metastases; the majority had
6 or fewer metastases, whereas a small minority exhibited
Frequency distribution for the numbers of metastases Figure 1
Frequency distribution for the numbers of metas-
tases. Frequency distributions for the number of hematoge-
nous metastases can be predicted based upon random 
counting statistics, modulated by regional organ blood flow 
heterogeneity. In this model the biological properties of the 
tumor cells and the host environment were otherwise 
assumed constant. The simulation was executed with a mean 
of 8 ± 7.6 (SD) metastases, in keeping with observations 
compiled from murine and human tumors.
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as many as 40 metastases. The numbers of metastases sus-
tained by individuals under identical conditions were
thus quite variable, but they were consistent with the
available clinical and pathological studies [27].
Simulations were also performed for the size distribution
of metastases in this hypothetical series of patients. A total
of 4,000 simulations yielded a mean metastasis size of 4 ×
108 cells (range 2 × 104 to 8 × 109 cells; SD 8 × 108 cells).
Figure 2 provides the frequency histogram for the loga-
rithm of the number of cells per metastasis, as determined
from the 4,000 simulations. The histogram approximated
a normal distribution, and was consistent with the availa-
ble data from human autopsy studies [17,31].
The final simulations were designed to emulate a hypo-
thetical case series of 50 cancer patients. As before, the
intrinsic biological properties of host and tumor were
assumed identical, the primary tumors were removed at
comparable times, and the resultant metastases were enu-
merated 12 volume-doubling times later.
Figure 3 provides the results from this simulated case
series: Fig. 3a gives the numbers of simulated metastases.
Six cases sustained no metastases; the majority of cases
sustained less than 10 metastases; three cases sustained
more than 20 metastases. Figure 3b provides the respec-
tive sizes of the metastases from each case. Most cases had
metastases that consisted of fewer than 109 cells. Both the
numbers and sizes of the metastases were highly variable,
despite the identical biological conditions prerequisite to
the simulations.
From Fig. 3b it can be seen that the majority of the simu-
lated metastases would have been so small as to be effec-
tively occult, given a detection threshold of 109 cells.
However, only a small number of additional volume dou-
blings would have been required for many of these occult
metastases to become overt.
To better demonstrate the kinetics of the transition from
occult to overt metastases, the proportion of 4,000 simu-
lated metastases that had reached a detection threshold of
109 cells was plotted versus the time interval from removal
of the primary tumor. Figure 4 illustrates this graph. After
a latent period of about a dozen doubling times, the first
metastases would have appeared. With about an addi-
tional 3 volume doubling times beyond this, a majority of
the remaining metastases would then have become detect-
able, as had been surmised from Fig. 3b.
The appearance of multiple overt metastases within a rel-
atively short time period could be directly related to the
growth time distribution for multiple metastases. As pre-
viously noted, this distribution can be approximated by
the normal distribution [31]. The narrower this distribu-
tion is, the more likely that multiple metastases would
seem to appear within a short time period.
Discussion
How well do these simulations represent reality? The
answer to this question depends, in part, upon the validity
of the two models the simulations were based upon, one
for the frequency distribution of the number of hematog-
enous metastases [29], the other for the size distribution
of metastases [31]. The frequency distribution of metas-
tases was derived from observations of thousands of
humans and animals afflicted with cancer [25-27,29], and
it was mechanistically explained in terms of the influence
of physiological variations in regional organ blood on
counting statistics [28,29,33]. The size distribution for
hematogenous metastases was derived from detailed indi-
vidual human autopsy studies of thousands of metastases,
which agreed well with the lognormal distribution
[17,30,31]. It was mechanistically based on the hypothe-
sis of normally distributed growth times for exponentially
growing metastases [31]. Both models seemed well
grounded on observation, and they both had plausible
mechanisms.
As a further requirement for the simulations to be realistic,
the underlying models needed to yield results that were
within the range of experience. Human data were not
available for the numbers of hematogenous metastases
Size distribution for metastases Figure 2
Size distribution for metastases. A model for the 
growth of metastases was based upon a stochastic birth 
process where the growth times of the individual colonies 
were normally distributed. Four thousand simulations were 
performed. The resultant frequency histogram for the loga-
rithm of the number of cells per metastasis is shown here, 
and it approximated a normal distribution (solid line). This 
was equivalent to a lognormal distribution for the sizes of 
metastases.
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Fifty simulations for the numbers and sizes of metastases Figure 3
Fifty simulations for the numbers and sizes of metastases. In these simulations the primary tumors were presumed 
successfully resected from each host. All biological properties of the tumors and hosts were assumed constant. The only 
sources for deviation were random chance and heterogeneities in regional organ blood flow. In each simulation there were no 
clinically detectable metastases at the time of surgery, and the individuals were restaged after a time to allow for 12 volume 
doublings. a. Simulated numbers of metastases. Using the same parameterization as employed in Fig. 1, six cases sus-
tained no metastases whereas the remaining cases sustained anywhere from one to just under forty metastases. b. Simulated 
sizes of metastases. The resultant sizes of metastases from each case are plotted here semi-logarithmically. The right axis 
provides the numbers of cells per metastasis; the left gives the corresponding diameters of the metastases. Many of these 
metastases would likely be below the threshold of conventional clinical detection (arbitrarily defined here as at 109 cells). Given 
additional time for growth the subclinical metastases would have also become overt.
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sustained by syngeneic hosts, injected with cells from the
same tumor and assessed at the same time in the natural
history of the disease; but murine data were [18,21,26].
The simulations for the numbers of metastases were thus
parameterised so as to fit within the observed range of the
murine B16 F10 melanoma data. A mean number of 8 ±
8 (SD) metastases was chosen, and with a variance to
mean ratio of σ2/µ~8, results which were similar to obser-
vations from clones of the B16 F10 murine melanoma in
experimental metastasis assays with age matched syngenic
mice [25]. These simulated results also fell within the
bounds of the more heterogeneous clinical and patholog-
ical observations from humans [27].
With regards to the parameterisation for the size distribu-
tion of metastases, the simulated volumes (mean ± SD,
0.4 ± 0.8 cm3), and their coefficient of variation (σ/µ~2),
fitted into the range observed from individual human
autopsy studies [17,30]. The predictions from both of
these Monte Carlo simulations were thus consistent with
laboratory and human data.
What insights did these simulations provide into metasta-
sis? The conventional model for hematogenous metasta-
sis involves multiple sequential steps – the primary tumor
must produce cells capable of metastasis, these cells must
intravasate, exfoliate, successfully traverse the circulation
system, arrest in a target organ favourable to growth,
extravasate, form micrometastases, induce angiogenesis,
and then proliferate [35,36]. At points along this pathway,
tumor cells may also die or become dormant. The even-
tual burden of metastases presumably reflects the kinetic
balances inherent to each step, as well as the relative time
periods spent in dormancy and proliferation. The biolog-
ical properties of the tumor cells, the host environment,
and the biophysical aspects of the transport processes
involved likely would affect metastasis, as would random
events [37].
Much has been said and written about metastasis being a
nonrandom process [38-43]. This dictum seems most
appropriate when restricted to the organ predilections
contingent to the seed and soil hypothesis [32,44], and to
the anatomic pathways of regional metastasis [45,46].
However, the influence of random chance in metastasis
has not as thoroughly been deliberated. To this end, the
simulations preformed here showed that both the num-
bers and sizes of metastases within an individual could be
affected in a major way by chance mechanisms.
At the same time the spurious underlying nature of metas-
tasis has been well apparent to experimentalists. In the
conventional experimental metastasis assay, and despite
efforts to keep conditions constant, when syngeneic age-
matched animals are injected with equal sized aliquots of
the same tumor cell suspension, the resultant numbers of
lung metastases can be quite variable [18-22]. Biologists
have come to rely upon statistical tests to compare the
metastatic potentials of different tumor variants; the
median or mean number of metastases per group would
then provide an index for the metastatic potential of the
tumor, and the random variability could be quantitated
by the variance of the number of metastases per each
group [25,26]. This variability can be significant and it
would be reasonable to postulate a similar degree of vari-
ability to be associated with individual human cases.
The real issue is that the burden of metastasis can be
attributed partly to the biological properties of the tumor
and partly to chance events. To understand how to use the
observed metastatic burden in clinical practice, one must
understand the relative importance of the deterministic
and random components. Clinicians cannot rely upon
multiple replicate observations, and their measured vari-
ance, to assess the random component as can be done in
the animal laboratory. We are left to extrapolate from the
laboratory experiments where the numbers of metastases
in otherwise identical circumstances can vary considera-
bly. The parameters of the simulations performed here
were chosen to emulate human and animal observations
as closely as possible. One obviously cannot prove that
there exists a large random component to the metastatic
burden by these means; however, one can provide a plau-
Detection of metastases Figure 4
Detection of metastases. The percentage of clinically 
detectable metastases relative to the total number of metas-
tases within a patient is plotted here versus the time interval 
from the removal of the primary tumor to detection. This 
plot was based upon the 4000 simulations cells. A latent 
period provided in Fig. 2, and the detection threshold was set 
at 109 was apparent, where the metastases remain clinically 
occult, followed by a period where the proportion of overt 
metastases rapidly increased.
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sible example for the potential degree of variability that
might be encountered in clinical situations.
Chance also seems to have a role in the relatively sudden
appearance of multiple metastases, in persons who have
previously been followed without apparent disease. Clin-
ical experience indicates that it is not unusual for multiple
metastases to seem to appear within a relative short time
interval [47-52]. From the simulations presented here,
such apparently synchronous emergence of multiple
metastases within an individual could be attributable to a
relatively compact distribution for their growth times.
Admittedly there are also cases where multiple asynchro-
nous metastases can manifest over a longer time course; in
these cases presumably this distribution would not be so
compact.
The aim of this study was to examine the variability in the
metastatic burden, under circumstances where the meta-
static potential of a tumor and the conditions within the
host for tumor metastasis and growth could be considered
constant. Earlier in this article, the significant variability
in the numbers of experimental and spontaneous metas-
tases amongst similarly treated animals was alluded to
[18,21,26,53]. Because of this variability, laboratory sci-
entists have come to rely upon multiple measurements
from identically treated animals in order to assess the met-
astatic potential of tumors. Indeed, the variability can be
such that animals from a treatment group might sustain
multiple metastases while others from the same group
remained metastasis-free. Similar disparities, if observed
in human clinical series, might be construed as to repre-
sent the differing biological behavior of individual tumors
[12-16]. However in the light of these experimental data,
and the simulations provided here, these variations could
reasonably be attributed to spurious events, rather than to
inherent biological differences. For this reason it would
appear to be difficult to draw inferences regarding the bio-
logical behavior of a tumor, based upon individual assess-
ments of tumor burden.
Conclusion
The burden of metastases sustained by an individual can
presumably be influenced by the intrinsic biology of the
tumor, the host microenvironment, the time available for
tumor growth, and by the interaction of chance events
with these processes. The origins of these chance events
are not entirely clear; this could include both physical and
biological processes. Nevertheless, such events could lead
to a wide variation in number and sizes of metastases,
under otherwise controlled conditions. The growth times
of individual metastases are also affected by chance. But
here the variability is more constrained, and consequently
multiple occult metastases within an individual may rela-
tively suddenly become clinically overt.
These particular kinetic properties of metastases, although
influenced by tumor and host biology, can thus also be
affected by chance, to a degree sufficient to potentially
obscure the underlying biology. Clinicians will com-
monly make an assessment of the nature of a particular
individual's cancer based upon the apparent burden of
metastases. This simulation demonstrates that stochastic
elements could potentially have a major influence on the
burden of metastasis, to the point that it would seem
unreliable, in any individual, to base assessments as to the
biological potential of the cancer on the metastatic bur-
den.
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PNB, Poisson negative binomial; PGF, probability gener-
ating function; CDF, cumulative distribution function;
SD, standard deviation.
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